関連する実験動画
Updated: Feb 24, 2026

05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.2K
マルチソースデータを活用した薬理ゲノムデータセット間の不整合解消による薬剤感受性予測
Xiaodi Li1, Trisha Das1,2, Kritib Bhattarai1,3
1Department of Artificial Intelligence and Informatics Research, Mayo Clinic, Rochester, MN, USA.
AMIA ... Annual Symposium proceedings. AMIA Symposium
|February 23, 2026
まとめ
本研究では、複数の薬理ゲノムデータセット間の不整合から学習することで薬剤応答予測を改善する計算モデル、集約学習(AL)を紹介します。この新しいアプローチは、バイオマーカー同定のためのモデル精度と一般化性能を向上させます。
科学分野:
- 計算生物学
- 薬理ゲノム学
- 生物医学データサイエンス
背景:
- 薬理ゲノムデータセットは、バイオマーカー同定と薬剤応答予測に不可欠である。
- 既存のモデルは、腫瘍内不均一性、実験的変動、細胞サブタイプの複雑さに起因する不整合により、しばしば性能が低下する。
- これらの不整合は、予測モデルの一般化を制限する。
主な方法:
- 集約学習(AL)に基づく新しい計算モデルを提案した。
- ALモデルは、Cancer Cell Line Encyclopedia(CCLE)、Genomics of Drug Sensitivity in Cancer(GDSC2)、cancer-genomics.org(gCSI)の3つの薬理ゲノムデータセットから得られた重複する不整合データポイントでトレーニングされた。
- ALモデルの性能を、Selecting Better(SB)、Result Average(RA)、Combining Data(CD)、Model Average(MA)の4つのベースライン法と比較した。
結論:
- 薬理ゲノムデータセットの内外の不整合に対処することは、薬剤応答予測モデルの改善に不可欠である。
- 提案された集約学習(AL)モデルは、堅牢で一般化可能な薬剤応答予測のための有望なソリューションを提供する。
- このアプローチは、より正確なバイオマーカー同定と治療選択を通じて、個別化医療を進歩させる可能性を秘めている。
関連する概念動画
Pharmacogenomics: Identification of New Drug Targets
29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Pharmacogenetics and Pharmacogenomics: Overview
51
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
51
Pharmacogenetics of Drug Metabolism: Overview
32
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
32
Analysis of Population Pharmacokinetic Data
843
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
843
Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26

